The Effect of Vancomycin and Third-Generation Cephalosporins on Prevalence of Vancomycin-Resistant Enterococci in 126 U.S. Adult Intensive Care Units

Scott K. Fridkin, MD;
Jonathan R. Edwards, MS;
Jeanne M. Courval, PhD;
Holly Hill, MD, PhD;
Fred C. Tenover, PhD;
Rachel Lawton, MPH;
Robert P. Gaynes, MD;
John E. McGowan, Jr., MD; and
for the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project and the National Nosocomial Infections Surveillance (NNIS) System Hospitals

From National Center for Infectious Diseases, U.S. Centers for Disease Control and Prevention, and Rollins School of Public Health, Emory University, Atlanta, Georgia.

View larger version:
- In this window
- In a new window
Figure. values were determined for the Spearman correlation coefficient ( = 0.44 [95% CI, 0.29 to 0.57]) and weighted linear regression (parameter estimate = 0.08; = 0.001). Correlation of the rate of parenteral vancomycin (defined daily doses per 1000 patient-days) and the prevalence of vancomycin-resistant enterococci (percentage of enterococci that are vancomycin resistant) in 126 intensive care units.PrP